Nanoparticles based therapeutic efficacy against Acanthamoeba: Updates and future prospect

Area of Science:

• Medical Microbiology
• Nanotechnology
• Infectious Diseases

Background:

• Acanthamoeba species cause severe human infections, including Acanthamoeba keratitis and granulomatous amoebic encephalitis.
• Current antimicrobial treatments for Acanthamoeba infections exhibit toxicity, side effects, and face challenges like drug resistance and cyst formation.
• Effective treatments for central nervous system infections must cross the blood-brain barrier.

Purpose of the Study:

• To provide a comprehensive overview of nanoparticle-based therapeutic strategies against Acanthamoeba.
• To summarize research on the efficacy of nanoparticles conjugated with drugs or natural compounds against Acanthamoeba.
• To highlight the potential of nanotechnology in overcoming limitations of current Acanthamoeba chemotherapy.

Main Methods:

• Review of existing research on nanoparticles tested against Acanthamoeba.
• Analysis of studies investigating nanoparticle-drug conjugates and nanoparticle-natural compound conjugates.
• Evaluation of nanoparticle efficacy against both trophozoite and cyst forms of Acanthamoeba.

Main Results:

• Various nanoparticles have been investigated for their effectiveness against Acanthamoeba.
• Nanoparticle-based drug delivery systems show potential in overcoming limitations of conventional chemotherapy.
• Research indicates efficacy of nanoparticles conjugated with drugs and/or natural compounds against Acanthamoeba.

Conclusions:

• Nanoparticle-based drug delivery presents an effective therapeutic strategy for Acanthamoeba infections.
• Nanoparticles can potentially mitigate issues of drug toxicity, resistance, and cyst formation.
• Further research into nanoparticle applications holds promise for improved Acanthamoeba treatment outcomes.